RRAS
Basic information
Region (hg38): 19:49635292-49640143
Links
Phenotypes
GenCC
Source:
- Noonan syndrome (Moderate), mode of inheritance: AD
- Noonan syndrome (Limited), mode of inheritance: AD
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the RRAS gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 67 | 69 | ||||
missense | 119 | 123 | ||||
nonsense | 1 | |||||
start loss | 3 | |||||
frameshift | 4 | |||||
inframe indel | 1 | |||||
splice donor/acceptor (+/-2bp) | 1 | |||||
splice region | 10 | 11 | 21 | |||
non coding | 29 | 10 | 45 | |||
Total | 0 | 1 | 135 | 99 | 12 |
Variants in RRAS
This is a list of pathogenic ClinVar variants found in the RRAS region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
19-49635346-G-A | Uncertain significance (Feb 04, 2022) | |||
19-49635571-C-T | not specified • RRAS-related disorder | Uncertain significance (May 28, 2023) | ||
19-49635572-T-C | not specified • RRAS-related disorder | Benign (Apr 27, 2021) | ||
19-49635581-G-A | Noonan syndrome • not specified | Likely benign (Feb 05, 2023) | ||
19-49635584-G-C | Noonan syndrome | Uncertain significance (Jun 26, 2018) | ||
19-49635587-C-T | Noonan syndrome • not specified | Uncertain significance (Dec 15, 2022) | ||
19-49635588-G-A | Noonan syndrome • RRAS-related disorder • not specified | Likely benign (Jun 14, 2022) | ||
19-49635590-A-G | Noonan syndrome | Uncertain significance (Jul 13, 2022) | ||
19-49635591-G-A | Noonan syndrome • not specified | Likely benign (May 17, 2022) | ||
19-49635602-C-T | Noonan syndrome • not specified | Uncertain significance (May 10, 2024) | ||
19-49635603-G-A | Noonan syndrome • RRAS-related disorder • not specified | Likely benign (Oct 17, 2022) | ||
19-49635606-C-A | Noonan syndrome • not specified | Uncertain significance (Apr 04, 2024) | ||
19-49635609-C-T | Noonan syndrome • not specified | Likely benign (Jul 08, 2024) | ||
19-49635610-T-C | Noonan syndrome • not specified | Uncertain significance (Nov 04, 2023) | ||
19-49635613-C-T | not specified | Uncertain significance (Nov 05, 2021) | ||
19-49635617-G-A | not specified | Uncertain significance (Jan 22, 2024) | ||
19-49635619-G-A | Noonan syndrome • not specified | Uncertain significance (Jul 14, 2022) | ||
19-49635620-C-T | not specified | Likely benign (Dec 07, 2021) | ||
19-49635623-T-C | Noonan syndrome | Uncertain significance (Aug 05, 2022) | ||
19-49635624-G-A | Noonan syndrome • RRAS-related disorder | Likely benign (Jul 28, 2023) | ||
19-49635633-C-T | Noonan syndrome • not specified • RRAS-related disorder | Benign/Likely benign (Nov 13, 2023) | ||
19-49635634-G-A | Noonan syndrome | Uncertain significance (May 12, 2022) | ||
19-49635635-G-A | Noonan syndrome | Uncertain significance (Aug 22, 2023) | ||
19-49635638-G-T | not specified | Uncertain significance (May 19, 2024) | ||
19-49635648-T-C | not specified | Likely benign (Jan 27, 2020) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
RRAS | protein_coding | protein_coding | ENST00000246792 | 6 | 4910 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.00466 | 0.888 | 125691 | 0 | 56 | 125747 | 0.000223 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.676 | 110 | 132 | 0.834 | 0.00000857 | 1379 |
Missense in Polyphen | 38 | 46.768 | 0.81253 | 487 | ||
Synonymous | -0.0423 | 59 | 58.6 | 1.01 | 0.00000420 | 450 |
Loss of Function | 1.37 | 5 | 9.56 | 0.523 | 4.53e-7 | 110 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.0000589 | 0.0000589 |
Ashkenazi Jewish | 0.000102 | 0.0000992 |
East Asian | 0.00 | 0.00 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.000478 | 0.000457 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.0000331 | 0.0000327 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Regulates the organization of the actin cytoskeleton (PubMed:16537651, PubMed:18270267). With OSPBL3, modulates integrin beta-1 (ITGB1) activity (PubMed:18270267). {ECO:0000269|PubMed:16537651, ECO:0000269|PubMed:18270267}.;
- Pathway
- Autophagy - animal - Homo sapiens (human);HTLV-I infection - Homo sapiens (human);Regulation of actin cytoskeleton - Homo sapiens (human);Mitophagy - animal - Homo sapiens (human);Axon guidance - Homo sapiens (human);cAMP signaling pathway - Homo sapiens (human);Apelin signaling pathway - Homo sapiens (human);C-type lectin receptor signaling pathway - Homo sapiens (human);Rap1 signaling pathway - Homo sapiens (human);Ras signaling pathway - Homo sapiens (human);MAPK signaling pathway - Homo sapiens (human);Phospholipase D signaling pathway - Homo sapiens (human);Proteoglycans in cancer - Homo sapiens (human);Cellular senescence - Homo sapiens (human);EGFR Inhibitor Pathway, Pharmacodynamics;Bisphosphonate Pathway, Pharmacodynamics;Vemurafenib Pathway, Pharmacodynamics;update your name in edit mode;G Protein Signaling Pathways;MAPK Signaling Pathway;Canonical and Non-canonical Notch signaling;MAPK and NFkB Signalling Pathways Inhibited by Yersinia YopJ;T-Cell antigen Receptor (TCR) pathway during Staphylococcus aureus infection;MAPK Cascade;Ras Signaling;Regulation of Actin Cytoskeleton;Developmental Biology;Regulation of Ras family activation;Neuronal System;Sema4D mediated inhibition of cell attachment and migration;Sema4D in semaphorin signaling;SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion;Semaphorin interactions;Neurotransmitter receptors and postsynaptic signal transmission;Transmission across Chemical Synapses;Plexin-D1 Signaling;Axon guidance;CREB phosphorylation through the activation of Ras;Post NMDA receptor activation events;Activation of NMDA receptor and postsynaptic events;Signaling events mediated by focal adhesion kinase;EPHB forward signaling
(Consensus)
Recessive Scores
- pRec
- 0.199
Intolerance Scores
- loftool
- 0.435
- rvis_EVS
- 0.24
- rvis_percentile_EVS
- 69.21
Haploinsufficiency Scores
- pHI
- 0.193
- hipred
- Y
- hipred_score
- 0.756
- ghis
- 0.530
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.590
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Rras
- Phenotype
- homeostasis/metabolism phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; neoplasm; immune system phenotype;
Zebrafish Information Network
- Gene name
- rras
- Affected structure
- vagal ganglion
- Phenotype tag
- abnormal
- Phenotype quality
- fused with
Gene ontology
- Biological process
- leukocyte differentiation;Ras protein signal transduction;negative regulation of cell migration;positive regulation of angiogenesis;regulation of protein kinase B signaling;face morphogenesis;regulation of ERK1 and ERK2 cascade
- Cellular component
- plasma membrane;focal adhesion;extracellular exosome
- Molecular function
- GTPase activity;protein binding;GTP binding;GDP binding;protein-containing complex binding